RXRX logo

RXRX EBITDA

Annual EBITDA

-$426.72 M
-$119.09 M-38.71%

December 31, 2024


Summary


Performance

RXRX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRXRXprofitabilitymetrics:

Quarterly EBITDA

-$165.34 M
-$77.42 M-88.05%

December 31, 2024


Summary


Performance

RXRX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRXRXprofitabilitymetrics:

TTM EBITDA

-$426.72 M
-$75.86 M-21.62%

December 31, 2024


Summary


Performance

RXRX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRXRXprofitabilitymetrics:

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

RXRX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-38.7%-88.0%-21.6%
3 y3 years-143.7%-88.0%-21.6%
5 y5 years-626.3%-88.0%-21.6%

RXRX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-143.7%at low-210.8%at low-143.7%at low
5 y5-year-626.3%at low-862.1%at low-2383.0%at low
alltimeall time-626.3%at low-862.1%at low-2383.0%at low

Recursion Pharmaceuticals EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
-$426.72 M(+38.7%)
-$165.34 M(+88.1%)
-$426.72 M(+21.6%)
Sep 2024
-
-$87.92 M(-0.9%)
-$350.86 M(+0.7%)
Jun 2024
-
-$88.70 M(+4.7%)
-$348.35 M(+5.3%)
Mar 2024
-
-$84.75 M(-5.3%)
-$330.81 M(+7.5%)
Dec 2023
-$307.63 M(+35.1%)
-$89.48 M(+4.8%)
-$307.63 M(+12.9%)
Sep 2023
-
-$85.41 M(+20.0%)
-$272.42 M(+11.4%)
Jun 2023
-
-$71.16 M(+15.6%)
-$244.45 M(+3.6%)
Mar 2023
-
-$61.58 M(+13.5%)
-$236.05 M(+3.7%)
Dec 2022
-$227.66 M
-$54.27 M(-5.5%)
-$227.67 M(-3.6%)
Sep 2022
-
-$57.44 M(-8.5%)
-$236.12 M(+5.7%)
Jun 2022
-
-$62.76 M(+18.0%)
-$223.45 M(+12.1%)
DateAnnualQuarterlyTTM
Mar 2022
-
-$53.20 M(-15.2%)
-$199.25 M(+13.8%)
Dec 2021
-$175.12 M(+114.3%)
-$62.72 M(+40.1%)
-$175.12 M(+28.0%)
Sep 2021
-
-$44.77 M(+16.1%)
-$136.82 M(+19.3%)
Jun 2021
-
-$38.57 M(+32.7%)
-$114.66 M(+22.5%)
Mar 2021
-
-$29.07 M(+19.1%)
-$93.58 M(+14.5%)
Dec 2020
-$81.70 M(+39.1%)
-
-
Dec 2020
-
-$24.41 M(+7.9%)
-$81.70 M(+42.6%)
Sep 2020
-
-$22.61 M(+29.3%)
-$57.29 M(+65.2%)
Jun 2020
-
-$17.49 M(+1.8%)
-$34.68 M(+101.8%)
Mar 2020
-
-$17.19 M
-$17.19 M
Dec 2019
-$58.76 M
-
-

FAQ

  • What is Recursion Pharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for Recursion Pharmaceuticals?
  • What is Recursion Pharmaceuticals annual EBITDA year-on-year change?
  • What is Recursion Pharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Recursion Pharmaceuticals?
  • What is Recursion Pharmaceuticals quarterly EBITDA year-on-year change?
  • What is Recursion Pharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for Recursion Pharmaceuticals?
  • What is Recursion Pharmaceuticals TTM EBITDA year-on-year change?

What is Recursion Pharmaceuticals annual EBITDA?

The current annual EBITDA of RXRX is -$426.72 M

What is the all time high annual EBITDA for Recursion Pharmaceuticals?

Recursion Pharmaceuticals all-time high annual EBITDA is -$58.76 M

What is Recursion Pharmaceuticals annual EBITDA year-on-year change?

Over the past year, RXRX annual EBITDA has changed by -$119.09 M (-38.71%)

What is Recursion Pharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of RXRX is -$165.34 M

What is the all time high quarterly EBITDA for Recursion Pharmaceuticals?

Recursion Pharmaceuticals all-time high quarterly EBITDA is -$17.19 M

What is Recursion Pharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, RXRX quarterly EBITDA has changed by -$77.42 M (-88.05%)

What is Recursion Pharmaceuticals TTM EBITDA?

The current TTM EBITDA of RXRX is -$426.72 M

What is the all time high TTM EBITDA for Recursion Pharmaceuticals?

Recursion Pharmaceuticals all-time high TTM EBITDA is -$17.19 M

What is Recursion Pharmaceuticals TTM EBITDA year-on-year change?

Over the past year, RXRX TTM EBITDA has changed by -$75.86 M (-21.62%)